K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Investigational treatment improves outcomes without complete complement blockade ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Wedbush initiated coverage on Dianthus Therapeutics Inc DNTH, noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the complement C1s protein.